First clinical application of silicon-based [¹⁸F]siPSMA-14 in prostate cancer patients: A proof-of-concept study
Jonathan Miksch, Elham Yousefzadeh-Nowshahr, Deni Hardiansyah, Gerhard Glatting, Christoph Solbach, Christian Bolenz, Friedemann Zengerling, Thomas Wiegel, Meinrad Beer, Vikas Prasad, Hans-Jürgen Wester, Ambros J. Beer, Wolfgang Thaiss · Nuklearmedizin - NuclearMedicine · 2025 · Heft 05 · S. 285-293
Bibliografische Angaben
Zusammenfassung
Abstract Aim Silicon-based ligands are of interest in increasingly used Prostate-specific membrane antigen (PSMA) tracers for prostate cancer (PCa) staging due to their simple and scalable production. Here, we present first data on dosimetry and biodistribution of the novel PSMA-specific tracer [¹⁸F]siPSMA-14. Methods Seven PCa patients referred for PSMA-PET/CT imaging were imaged at 60 and 120 min p.i. (T1 and T3), without forced diuresis, to assess organ absorbed (AD) and effective doses (ED). We matched seven of subsequent 134 patients imaged at 90 min. p. i. (T2) to the initial seven patients according to di…
